This article is more than 5 years old. Information may no longer be current.

FDA OKs new drug application for Topicort to treat plaque psoriasis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has approved Taro Pharmaceutical Industries’ new drug application for its topical corticosteroid spray for treating plaque psoriasis, the company announced.

Topicort (desoximetasone) topical spray 0.25% is indicated for plaque psoriasis in patients aged 18 years and older, according to a Taro press release.

Nationwide sales of corticosteroid sprays generate $100 million annually, Taro reported.

Taro already markets four other Topicort prescribing options, including creams, gel and ointment, for the treatment of scalp psoriasis and dermatitis.